Single Bevacizumab Dose Sustains Trabeculectomy Success
A study found that a single dose of intravitreal bevacizumab during trabeculectomy significantly improved surgical success over three years compared to a placebo. Patients receiving bevacizumab had a lower need for topical intraocular pressure-lowering drops. The results suggest that the benefits of bevacizumab persist long-term in glaucoma surgery.
- ▪Intravitreal bevacizumab was associated with more durable surgical success over three years compared to placebo.
- ▪At 36 months, 92.3% of patients receiving bevacizumab achieved complete success compared to 71.2% in the placebo group.
- ▪Fewer patients who received bevacizumab required topical intraocular pressure-lowering drops at most postoperative visits.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Compared with placebo, intravitreal bevacizumab administered as a single intraoperative dose during trabeculectomy with mitomycin C was associated with more durable surgical success over 3 years and a reduced need for topical intraocular pressure-lowering eye drops.METHODOLOGY:Researchers conducted a 3-year follow-up study of a clinical trial to test whether a single intravitreal injection of bevacizumab during trabeculectomy continued to improve surgical success.Between July 2016 and September 2018, 131 patients who needed primary or redo trabeculectomy or phacotrabeculectomy for progressive glaucoma were enrolled and randomly assigned to receive a single intraoperative intravitreal injection of bevacizumab (n = 65; mean age, 77.7 years; 56.9% male) or placebo (n = 66; mean age,…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
